DeepMed Research

Maria Sklodowska-Curie National Research Institute of Oncology

🇵🇱Poland

Country: 🇵🇱Poland

Ownership: Private

Established: 1951-01-01

Employees: -

Market Cap: -

Website: https://www.pib-nio.pl/

Clinical Trials

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer
Uterine Cervical Cancer
Uterine Corpus Cancer
Malignant Melanoma
Clear Cell Renal Cell Carcinoma

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 60

Registration Number: NCT06976021

Functional Abdominal Wall Reconstruction

Active, not recruiting

Conditions: Prune Belly Syndrome

First Posted Date: 2025-04-15

Last Posted Date: 2025-04-15

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 7

Registration Number: NCT06928974

Locations: 🇵🇱
Maria Sklodowska Curie Memorial National Cancer Center, Gliwice, Poland

Stereotactic Radiosurgery in the Treatment of Essential Tremor

Phase 2

Recruiting

Conditions: Essential Tremor

First Posted Date: 2025-02-12

Last Posted Date: 2025-02-12

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 42

Registration Number: NCT06821906

Locations: 🇵🇱
Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Radiation: Preoperative radiation therapy
Drug: Keytruda
Drug: Placebo

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 78

Registration Number: NCT06472583

Locations: 🇵🇱
Maria Sklodowska-Curie National Research Institute of Oncology , Gliwice Branch, Gliwice, Poland

Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

Not Applicable

Recruiting

Conditions: Head and Neck Cancer

Interventions: Radiation: Stereotactic radiotherapy boost

First Posted Date: 2024-06-25

Last Posted Date: 2024-06-25

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 80

Registration Number: NCT06472570

Locations: 🇵🇱
1st Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch,, Gliwice, Gliwicw, Poland

177Lu-PSMA As a Systemic Adjuvant Treatment in Patients with High and Very High Risk Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Lutetium (177Lu) vipivotide tetraxetan

First Posted Date: 2024-06-10

Last Posted Date: 2025-02-10

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 200

Registration Number: NCT06449781

Locations: 🇵🇱
Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland

Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy

Phase 2

Recruiting

Conditions: Radiotherapy
Local Recurrence of Malignant Tumor of Prostate

Interventions: Radiation: Stereotactic Body Radiotherapy

First Posted Date: 2024-01-11

Last Posted Date: 2025-03-13

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 55

Registration Number: NCT06201078

Locations: 🇵🇱
Maria Sklodowska Memorial Research Institute of Oncology, Gliwice, Poland

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial

Phase 2

Withdrawn

Conditions: Adenoid Cystic Carcinoma

Interventions: Drug: Lutetium (177Lu) vipivotide tetraxetan

First Posted Date: 2024-01-10

Last Posted Date: 2025-02-10

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 32

Registration Number: NCT06199453

Locations: 🇵🇱
Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

Pembrolizumab in Combination with Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients with Soft Tissue Sarcoma - EFTISARC-NEO Trial

Phase 2

Active, not recruiting

Conditions: Neoadjuvant
Radiation Therapy
Immunotherapy
Sarcoma,Soft Tissue

Interventions: Drug: Pembrolizumab, Eftilagimod alpha

First Posted Date: 2023-11-13

Last Posted Date: 2025-02-10

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 40

Registration Number: NCT06128863

Locations: 🇵🇱
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy

Not Applicable

Recruiting

Conditions: Pharynx Carcinoma
Larynx Carcinoma
Paranasal Sinus Carcinoma
Squamous Cell Carcinoma of Oral Cavity

Interventions: Other: Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy

First Posted Date: 2023-08-15

Last Posted Date: 2023-08-15

Lead Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology

Target Recruit Count: 40

Registration Number: NCT05992610

Locations: 🇵🇱
The Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Gliwice, Gliwice, Silesia, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy